Two studies out of Europe aimed to give data on which patients with HIV benefit most from lipid-lowering medications, but they both ultimately concluded that better CVD risk-assessment tools—targeted specifically for PLWH—are needed.
Feb. 11, 2021: Early comorbidity development among women living with HIV; type 2 heart attack frequency; assessing European-based CVD assessment tools; long-term cognitive dysfunction and HIV/hepatitis coinfection.
Nov. 19, 2020: Metformin's effect on weight and gut microbiota; integrase and cardiometabolics in women with HIV; ongoing link between HIV, smoking, and cancer; how early HIV treatment initiation impacts future cervical cancer outcomes.
Oct. 8, 2020: HPV-related cancer risk among women living with HIV; the interplay between HIV, HBV, and liver disease; Framingham vs. other tools to gauge statin value; integrase inhibitors, weight gain, and menopause.
Sept. 24, 2020: HIV adherence cohorts usually fail to reflect the diversity of the epidemic; HIV thrives in deprived neighborhoods; rethinking barriers to rapid HIV treatment initiation; long-term adverse events on INSTIs vs. efavirenz.
Aug. 27, 2020: Traditional CVD risk calculation tools falter for transgender women; switching to B/F/TAF despite NRTI resistance; how tenofovir has altered the HBV landscape; syndemic effects on viral load and blood pressure.
Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.
Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.
These studies presented at AIDS 2020 explore the benefits and challenges.
People living with HIV in the U.S. are experiencing increases in body mass index at a rate three times greater than that of the general U.S. population, according to new research presented at AIDS 2020.